Ken Eguchi

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Strategies to augment anti-cancer immune responses have recently demonstrated therapeutic utility. To date clinical success has been achieved through targeting co-inhibitory checkpoints such as CTLA-4, PD-1, and PD-L1. However, approaches that target co-activatory pathways are also being actively being developed. Here we report that the novel TLR7-selective(More)
  • 1